DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported positive interim results from its Phase 2 study of DM199 for treating preeclampsia, according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE